PBA
GMAB icon

Paradigm Biocapital Advisors’s Genmab GMAB Stock Holding History

Paradigm Biocapital Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361M Buy
13,133,131
+5,165,295
+65% +$137M 6.76% 4
2026
Q1 		$214M Buy
7,967,836
+928,002
+13% +$27.8M 4.37% 6
2025
Q4 		$217M Buy
7,039,834
+3,222,983
+84% +$100M 5.53% 4
2025
Q3 		$117M Buy
+3,816,851
New +$93M 3.33% 8

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Paradigm Biocapital Advisors's GMAB Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Genmab (GMAB) stake by 65% in Q2 2026, buying an estimated $137M and bringing the position to 13,133,131 shares worth $361M. The position accounts for 6.76% of the portfolio, ranked #4.

Paradigm Biocapital Advisors first reported a position in GMAB in Q3 2025 and has held it in 4 quarters since. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Paradigm Biocapital Advisors held 13,133,131 shares of Genmab worth $361M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 5,165,295 Genmab shares in Q2 2026, an estimated $137M.
  • Genmab made up 6.76% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #4 holding.
  • Paradigm Biocapital Advisors first reported a position in Genmab in Q3 2025 and has held it in 4 quarters since.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.